Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Organogenesis (NASDAQ:ORGO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain [Yahoo! Finance]
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain